Summary
Global Markets Direct’s, ‘Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Review, H1 2016’, provides an overview of the Adenocarcinoma Of The Gastroesophageal Junction pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Adenocarcinoma Of The Gastroesophageal Junction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Adenocarcinoma Of The Gastroesophageal Junction and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Adenocarcinoma Of The Gastroesophageal Junction
- The report reviews pipeline therapeutics for Adenocarcinoma Of The Gastroesophageal Junction by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Adenocarcinoma Of The Gastroesophageal Junction therapeutics and enlists all their major and minor projects
- The report assesses Adenocarcinoma Of The Gastroesophageal Junction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Adenocarcinoma Of The Gastroesophageal Junction
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Adenocarcinoma Of The Gastroesophageal Junction
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Adenocarcinoma Of The Gastroesophageal Junction pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
AB Science SA
AbbVie Inc.
Advenchen Laboratories, LLC
Amgen Inc.
ArQule, Inc.
AstraZeneca Plc
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
Cerulean Pharma, Inc.
Daiichi Sankyo Company, Limited
Dr. Reddy's Laboratories Limited
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Ganymed Pharmaceuticals AG
Genentech, Inc.
Gilead Sciences, Inc.
Hutchison MediPharma Limited
Imugene Limited
Johnson & Johnson
Mebiopharm Co., Ltd.
MedImmune, LLC
Merck & Co., Inc.
Merck KGaA
Millennium Pharmaceuticals, Inc.
Novartis AG
Oncobiologics, Inc.
Panacea Biotec Limited
Sanofi
Taiho Pharmaceutical Co., Ltd.
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Adenocarcinoma Of The Gastroesophageal Junction Overview 8
Therapeutics Development 9
Pipeline Products for Adenocarcinoma Of The Gastroesophageal Junction - Overview 9
Pipeline Products for Adenocarcinoma Of The Gastroesophageal Junction - Comparative Analysis 10
Adenocarcinoma Of The Gastroesophageal Junction - Therapeutics under Development by Companies 11
Adenocarcinoma Of The Gastroesophageal Junction - Therapeutics under Investigation by Universities/Institutes 13
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Adenocarcinoma Of The Gastroesophageal Junction - Products under Development by Companies 17
Adenocarcinoma Of The Gastroesophageal Junction - Products under Investigation by Universities/Institutes 20
Adenocarcinoma Of The Gastroesophageal Junction - Companies Involved in Therapeutics Development 21
AB Science SA 21
AbbVie Inc. 22
Advenchen Laboratories, LLC 23
Amgen Inc. 24
ArQule, Inc. 25
AstraZeneca Plc 26
Boehringer Ingelheim GmbH 27
Boston Biomedical, Inc. 28
Bristol-Myers Squibb Company 29
Cerulean Pharma, Inc. 30
Daiichi Sankyo Company, Limited 31
Dr. Reddy's Laboratories Limited 32
Eli Lilly and Company 33
F. Hoffmann-La Roche Ltd. 34
Ganymed Pharmaceuticals AG 35
Genentech, Inc. 36
Gilead Sciences, Inc. 37
Hutchison MediPharma Limited 38
Imugene Limited 39
Johnson & Johnson 40
Mebiopharm Co., Ltd. 41
MedImmune, LLC 42
Merck & Co., Inc. 43
Merck KGaA 44
Millennium Pharmaceuticals, Inc. 45
Novartis AG 46
Oncobiologics, Inc. 47
Panacea Biotec Limited 48
Sanofi 49
Taiho Pharmaceutical Co., Ltd. 50
Adenocarcinoma Of The Gastroesophageal Junction - Therapeutics Assessment 51
Assessment by Monotherapy Products 51
Assessment by Combination Products 52
Assessment by Target 53
Assessment by Mechanism of Action 56
Assessment by Route of Administration 59
Assessment by Molecule Type 61
Drug Profiles 63
(tipiracil hydrochloride + trifluridine) - Drug Profile 63
AL-3818 - Drug Profile 66
alisertib - Drug Profile 68
alpelisib - Drug Profile 73
AMG-337 - Drug Profile 75
atezolizumab - Drug Profile 76
avelumab - Drug Profile 81
AZD-4547 - Drug Profile 83
AZD-6738 - Drug Profile 85
BI-853520 - Drug Profile 87
cabazitaxel - Drug Profile 88
catumaxomab - Drug Profile 90
Cellular Immunotherapy for Oncology - Drug Profile 93
ceritinib - Drug Profile 94
CRLX-101 - Drug Profile 97
DS-8201 - Drug Profile 100
durvalumab - Drug Profile 101
durvalumab + tremelimumab - Drug Profile 106
emibetuzumab - Drug Profile 108
erdafitinib - Drug Profile 109
GS-5745 - Drug Profile 111
Her-VAXX - Drug Profile 113
ibrutinib - Drug Profile 115
IMAB-362 - Drug Profile 123
indusatumab vedotin - Drug Profile 125
ipatasertib - Drug Profile 127
ipilimumab - Drug Profile 129
LAG-525 - Drug Profile 134
LY-3127804 - Drug Profile 135
masitinib - Drug Profile 136
MBP-426 - Drug Profile 142
merestinib - Drug Profile 144
napabucasin - Drug Profile 145
panitumumab - Drug Profile 148
PDR-001 - Drug Profile 152
pembrolizumab - Drug Profile 153
pertuzumab - Drug Profile 164
ramucirumab - Drug Profile 168
SAR-408701 - Drug Profile 174
savolitinib - Drug Profile 175
solitomab - Drug Profile 178
sonidegib phosphate - Drug Profile 179
TAK-117 - Drug Profile 183
tivantinib - Drug Profile 184
trastuzumab biosimilar - Drug Profile 187
trastuzumab biosimilar - Drug Profile 189
trastuzumab biosimilar - Drug Profile 190
trastuzumab biosimilar - Drug Profile 191
tremelimumab - Drug Profile 192
Adenocarcinoma Of The Gastroesophageal Junction - Recent Pipeline Updates 195
Adenocarcinoma Of The Gastroesophageal Junction - Dormant Projects 316
Adenocarcinoma Of The Gastroesophageal Junction - Discontinued Products 317
Adenocarcinoma Of The Gastroesophageal Junction - Product Development Milestones 318
Featured News & Press Releases 318
Appendix 324
Methodology 324
Coverage 324
Secondary Research 324
Primary Research 324
Expert Panel Validation 324
Contact Us 324
Disclaimer 325
List of Tables
Number of Products under Development for Adenocarcinoma Of The Gastroesophageal Junction, H1 2016 13
Number of Products under Development for Adenocarcinoma Of The Gastroesophageal Junction - Comparative Analysis, H1 2016 14
Number of Products under Development by Companies, H1 2016 15
Number of Products under Development by Companies, H1 2016 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H1 2016 17
Comparative Analysis by Late Stage Development, H1 2016 18
Comparative Analysis by Clinical Stage Development, H1 2016 19
Comparative Analysis by Early Stage Development, H1 2016 20
Products under Development by Companies, H1 2016 21
Products under Development by Companies, H1 2016 (Contd..1) 22
Products under Development by Companies, H1 2016 (Contd..2) 23
Products under Investigation by Universities/Institutes, H1 2016 24
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by AB Science SA, H1 2016 25
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by AbbVie Inc., H1 2016 26
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Advenchen Laboratories, LLC, H1 2016 27
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Amgen Inc., H1 2016 28
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by ArQule, Inc., H1 2016 29
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by AstraZeneca Plc, H1 2016 30
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Boehringer Ingelheim GmbH, H1 2016 31
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Boston Biomedical, Inc., H1 2016 32
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Bristol-Myers Squibb Company, H1 2016 33
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Cerulean Pharma, Inc., H1 2016 34
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 35
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Dr. Reddy's Laboratories Limited, H1 2016 36
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Eli Lilly and Company, H1 2016 37
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 38
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Ganymed Pharmaceuticals AG, H1 2016 39
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Genentech, Inc., H1 2016 40
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Gilead Sciences, Inc., H1 2016 41
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Hutchison MediPharma Limited, H1 2016 42
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Imugene Limited, H1 2016 43
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Johnson & Johnson, H1 2016 44
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Mebiopharm Co., Ltd., H1 2016 45
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by MedImmune, LLC, H1 2016 46
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Merck & Co., Inc., H1 2016 47
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Merck KGaA, H1 2016 48
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 49
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Novartis AG, H1 2016 50
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Oncobiologics, Inc., H1 2016 51
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Panacea Biotec Limited, H1 2016 52
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Sanofi, H1 2016 53
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2016 54
Assessment by Monotherapy Products, H1 2016 55
Assessment by Combination Products, H1 2016 56
Number of Products by Stage and Target, H1 2016 58
Number of Products by Stage and Mechanism of Action, H1 2016 61
Number of Products by Stage and Route of Administration, H1 2016 64
Number of Products by Stage and Molecule Type, H1 2016 66
Adenocarcinoma Of The Gastroesophageal Junction Therapeutics - Recent Pipeline Updates, H1 2016 199
Adenocarcinoma Of The Gastroesophageal Junction - Dormant Projects, H1 2016 320
Adenocarcinoma Of The Gastroesophageal Junction - Discontinued Products, H1 2016 321
List of Figures
Number of Products under Development for Adenocarcinoma Of The Gastroesophageal Junction, H1 2016 13
Number of Products under Development for Adenocarcinoma Of The Gastroesophageal Junction - Comparative Analysis, H1 2016 14
Number of Products under Development by Companies, H1 2016 15
Comparative Analysis by Clinical Stage Development, H1 2016 19
Assessment by Monotherapy Products, H1 2016 55
Assessment by Combination Products, H1 2016 56
Number of Products by Top 10 Targets, H1 2016 57
Number of Products by Stage and Top 10 Targets, H1 2016 57
Number of Products by Top 10 Mechanism of Actions, H1 2016 60
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 60
Number of Products by Routes of Administration, H1 2016 63
Number of Products by Stage and Routes of Administration, H1 2016 63
Number of Products by Molecule Types, H1 2016 65
Number of Products by Stage and Molecule Types, H1 2016 65
